198 related articles for article (PubMed ID: 30651764)
1. Comparison of neuroendocrine dysfunction in patients with adamantinomatous and papillary craniopharyngiomas.
Feng Y; Ni M; Wang YG; Zhong LY
Exp Ther Med; 2019 Jan; 17(1):51-56. PubMed ID: 30651764
[TBL] [Abstract][Full Text] [Related]
2. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
Esheba GE; Hassan AA
J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and factors influencing hypothalamic pituitary dysfunction in patients with craniopharyngioma.
Guo Y; Pei L; Li Y; Li C; Gui S; Ni M; Liu P; Zhang Y; Zhong L
Front Endocrinol (Lausanne); 2023; 14():1180591. PubMed ID: 37324266
[TBL] [Abstract][Full Text] [Related]
4. Comparison of central diabetes insipidus (antidiuretic hormone deficiency) and stalk effect in patients with adamantinomatous and papillary craniopharyngioma.
Feng Y; Zhong L
Acta Neurol Belg; 2024 Apr; ():. PubMed ID: 38669000
[TBL] [Abstract][Full Text] [Related]
5. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
6. Growth patterns of craniopharyngiomas: clinical analysis of 226 patients.
Pan J; Qi S; Liu Y; Lu Y; Peng J; Zhang X; Xu Y; Huang GL; Fan J
J Neurosurg Pediatr; 2016 Apr; 17(4):418-33. PubMed ID: 26636252
[TBL] [Abstract][Full Text] [Related]
7. Craniopharyngioma involving the anterior, middle, and posterior cranial fossa in adults: A case report.
Tian B; Li M; Du X; Zhou H; Zhou K; Li S
Front Neurol; 2023; 14():1098600. PubMed ID: 36779068
[TBL] [Abstract][Full Text] [Related]
8. Harvey Cushing's craniopharyngioma treatment: Part 1. Identification and clinicopathological characterization of this challenging pituitary tumor.
Pascual JM; Prieto R; Barrios L
J Neurosurg; 2018 Oct; 131(3):949-963. PubMed ID: 30497204
[TBL] [Abstract][Full Text] [Related]
9. Association of histological subtype with risk of recurrence in craniopharyngioma patients: a systematic review and meta-analysis.
Wu J; Wu X; Yang YQ; Ding H; Yang L; Bao YY; Zhou L; Yang CX; Hong T
Neurosurg Rev; 2022 Feb; 45(1):139-150. PubMed ID: 34159471
[TBL] [Abstract][Full Text] [Related]
10. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
[TBL] [Abstract][Full Text] [Related]
11. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Endocrine and Metabolic Comorbidities in a National Cohort of Patients with Craniopharyngioma.
Jazbinšek S; Kolenc D; Bošnjak R; Faganel Kotnik B; Zadravec Zaletel L; Jenko Bizjan B; Vipotnik Vesnaver T; Battelino T; Janež A; Jensterle M; Kotnik P
Horm Res Paediatr; 2020; 93(1):46-57. PubMed ID: 32460296
[TBL] [Abstract][Full Text] [Related]
13. Papillary craniopharyngioma in a patient following resection of nonfunctioning pituitary adenoma: illustrative case.
Park DJ; Mishra A; Golub D; Li JY; Black KS; Schulder M
J Neurosurg Case Lessons; 2021 Jan; 1(2):CASE2063. PubMed ID: 35854932
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological Features of Craniopharyngioma: A 15-Year Study From a Tertiary Care Center in Pakistan.
Haroon S; Afzal A; Zia S; Ali SJ; Zia F; Shamail F; Irfan M; Hashmi AA
Cureus; 2021 Mar; 13(3):e14153. PubMed ID: 33936868
[TBL] [Abstract][Full Text] [Related]
15. EpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathke's cleft cysts.
Thimsen V; Hölsken A; Buchfelder M; Flitsch J; Fahlbusch R; Stefanits H; Losa M; Jones DT; Buslei R
Sci Rep; 2016 Jul; 6():29731. PubMed ID: 27431859
[TBL] [Abstract][Full Text] [Related]
16. Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.
Erfurth EM
J Intern Med; 2023 Sep; 294(3):269-280. PubMed ID: 37424210
[TBL] [Abstract][Full Text] [Related]
17. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.
Liu Y; Wang CH; Li DL; Zhang SC; Peng YP; Peng JX; Song Y; Qi ST; Pan J
Oncotarget; 2016 Aug; 7(31):50564-50574. PubMed ID: 27409178
[TBL] [Abstract][Full Text] [Related]
18. Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study.
Mukada N; Tosaka M; Matsumura N; Yamaguchi R; Aihara M; Isoda K; Higuchi T; Tsushima Y; Yokoo H; Yoshimoto Y
Sci Rep; 2021 Jan; 11(1):126. PubMed ID: 33420213
[TBL] [Abstract][Full Text] [Related]
19. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome.
Weiner HL; Wisoff JH; Rosenberg ME; Kupersmith MJ; Cohen H; Zagzag D; Shiminski-Maher T; Flamm ES; Epstein FJ; Miller DC
Neurosurgery; 1994 Dec; 35(6):1001-10; discussion 1010-1. PubMed ID: 7885544
[TBL] [Abstract][Full Text] [Related]
20. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
